January 27, 2016

Dear SoonerCare Provider,

The Oklahoma Health Care Authority is engaged in an effort to improve cost effective utilization of non-steroidal anti-inflammatory drugs (NSAIDs) and topical corticosteroids by our members. The purpose of this fax is to provide updates regarding NSAID and topical corticosteroid coverage.

**Effective February 16th, 2016, the following changes will be made to the NSAID category:**

1. The following NSAIDs will move from Tier-1 to Tier-2:
   a. Lodine® (etodolac) 200mg and 300mg capsules
   b. Lodine XL® (etodolac extended-release) 400mg, 500mg, and 600mg tablets
   c. Meclomen® (meclofenamate) 50mg and 100mg capsules
   d. Anaprox® (naproxen sodium) 275mg and 550mg tablets
   e. Daypro® (oxaprozin) 600mg tablets
   f. Tolectin® (tolmetin) 200mg and 600mg tablets; 400mg capsules
2. Voltaren® (diclofenac sodium) 25mg tablets will have a quantity limit of 60 tablets per 30 days.

Updated versions of prior authorization criteria for NSAIDs can be downloaded from [www.okhca.org/pa](http://www.okhca.org/pa), by selecting “Skeletal System.”

**Effective February 16th, 2016, the following changes will be made to the Topical Corticosteroid category:**

1. The following topical corticosteroids will move from Tier-1 to Tier-2:
   a. Diflorasone diacetate 0.05% (Apexicon®, Apexicon E®) cream and ointment
   b. Halobetasol propionate (Ultravate®) ointment
   c. Clobetasol propionate 0.05% (Temovate®) cream and ointment
   d. Hydrocortisone valerate 0.2% cream
   e. Fluocinolone acetonide 0.01% (Synalar®, Derma-Smooth®, Derma-Smooth FS®) solution and oil
2. Fluocinonide 0.05% solution and betamethasone dipropionate 0.05% (Diprosone®) ointment will be moved from Tier-2 to Tier-1.

Updated versions of prior authorization criteria for topical corticosteroids can be downloaded from [www.okhca.org/pa](http://www.okhca.org/pa), by selecting “Topical.”

We anticipate the Tier-1 medications will meet the needs of your patients. However, if they do not, you may choose to submit a prior authorization for consideration, including patient-specific, clinically significant supporting information for use of the requested medication.

Thank you for the services you provide to Oklahomans insured by SoonerCare!